Search

Zai Lab Ltd ADR

Cerrado

SectorSanidad

24.08 0.21

Resumen

Variación precio

24h

Actual

Mínimo

23.99

Máximo

24.2

Métricas clave

By Trading Economics

Ingresos

191K

-51M

Ventas

6.7M

106M

BPA

-0.46

Margen de beneficios

-47.808

Empleados

1,784

EBITDA

-2.1M

-46M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+62.94% upside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

892M

2.9B

Apertura anterior

23.87

Cierre anterior

24.08

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

89 / 339 Clasificación en Healthcare

Zai Lab Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2026, 12:41 UTC

News

Solana is trading higher as investor interest in cryptocurrency strengthens, aided by positive momentum from Ethereum and Pepeto's successful presale raising $10.96 million.

12 sept 2026, 00:06 UTC

Macro News
Macro Event
News

Bitcoin trades higher, nearing $79,000, as the market rebounds from $388 million in liquidations amid inflation concerns and declining crude oil prices.

12 sept 2026, 00:01 UTC

News

Kroger Co reported mixed second-quarter results, with shares lower in after-market trading. EPS guidance for the fiscal year is set between $5.10 and $5.30.

12 sept 2026, 00:01 UTC

Social Media
News

Scholar Rock Holding Corp shares rose in after-market trading following FDA approval of ISEMBYLD for spinal muscular atrophy, with commercial supply set to begin shortly.

12 sept 2026, 00:01 UTC

News

Nasdaq Inc announced a $100 million investment in Payward to develop blockchain-based equities, launching Nasdaq Equity Tokens in 2027. Shares traded higher in after-market hours.

12 sept 2026, 00:01 UTC

News
Social Media

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

12 sept 2026, 00:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion common stock offering announcement, raising investor concerns over potential dilution.

11 sept 2026, 23:56 UTC

News

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

11 sept 2026, 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

11 sept 2026, 23:26 UTC

News

Bentley Systems declared a quarterly dividend of $0.07 per share, scheduled for September 29, 2026, with shares trading higher in after-market hours.

11 sept 2026, 23:16 UTC

News

Carriage Services Inc shares higher in after-hours trading, following a Friday close. Analysts set an average price target of $51.00, indicating potential upside.

11 sept 2026, 23:06 UTC

Macro Event
News

Ethereum is higher in Friday's session, recovering after four days of declines. The asset remains above its 20-day moving average amid rising inflation pressures.

11 sept 2026, 23:06 UTC

Macro Event
News

Ethereum is rising during Friday's session, supported by recent inflation data and fluctuating crude oil prices. The asset remains above its 20-day moving average.

11 sept 2026, 23:01 UTC

Social Media
News

Oracle Corp's after-market shares declined following a $700 million expansion of its restructuring plan, raising total costs to $2.8 billion amid financial pressures.

11 sept 2026, 23:01 UTC

News

Nasdaq Inc. shares rose in after-market trading following a $100 million investment in Payward to develop Nasdaq Equity Tokens, set to launch in 2027.

11 sept 2026, 23:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion stock offering announcement, raising investor concerns about potential dilution.

11 sept 2026, 22:51 UTC

News
Social Media

Scholar Rock Holding Corp gains after FDA approves ISEMBYLD for spinal muscular atrophy, with a U.S. launch set to begin shortly.

11 sept 2026, 22:01 UTC

News

Estée Lauder Companies secured a legal win against Walmart over counterfeit products, but shares are trading lower in after-market hours amid ongoing retail sector concerns.

11 sept 2026, 21:31 UTC

News

Warner Bros Discovery Inc. shares are higher in after-market hours following reports of Paramount's settlement talks with state attorneys general over its acquisition proposal.

11 sept 2026, 20:51 UTC

News

Ralph Lauren Corp's Board declared a quarterly dividend of $1.00 per share, and shares are trading higher in after-market hours.

11 sept 2026, 20:09 UTC

News

1-800-Flowers.Com Inc shares are lower after reporting Q2 revenue of $293.1 million and a non-GAAP loss of $0.80 per share.

11 sept 2026, 20:09 UTC

News

Century Communities plans to open Grand Oaks of Callaway in Florida on September 26, featuring homes starting from the upper $200s. Shares are gaining.

11 sept 2026, 20:09 UTC

News

Columbia Sportswear appoints Peter Rauch as President of Mountain Hardwear, effective September 28. Shares are higher today, despite pulling back from an earlier session high.

11 sept 2026, 20:09 UTC

News

Clear Secure shares are lower after DA Davidson analyst Wyatt Swanson cut the price target to $45.00 from $55.00 while maintaining a Neutral rating.

11 sept 2026, 20:09 UTC

News

Carvana Co's shares are lower today, continuing a downward trend amid institutional investment activity and persistent inflation pressures indicated by recent CPI data.

11 sept 2026, 20:09 UTC

News

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

11 sept 2026, 20:09 UTC

News
Social Media
Correlated Moves

Snowflake Inc. shares are declining amid insider selling by director Benoit Dageville, who sold 50,000 shares at $335.72 on September 9.

11 sept 2026, 20:09 UTC

News
Social Media

Advanced Micro Devices shares are higher today following positive growth projections for its server and data center businesses, potentially exceeding $65 billion by Q4 2026.

11 sept 2026, 20:09 UTC

News

Intercontinental Exchange sponsors the 9/11 Day of Service initiative. Shares are advancing during Friday's trading, reflecting positive momentum since Thursday's close.

11 sept 2026, 20:09 UTC

News
Social Media

Marvell Technology reports fiscal Q2 revenue of $2.73 billion, exceeding estimates. Shares are higher amid strong demand for AI networking and advanced technologies.

Comparación entre iguales

Cambio de precio

Zai Lab Ltd ADR previsión

Precio Objetivo

By TipRanks

62.94% repunte

Estimación a 12 Meses

Media 39.333 USD  62.94%

Máximo 45 USD

Mínimo 36 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zai Lab Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

89 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat